Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 530549 | NSE: SHILPAMED

NSE BSE
660.20
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  601.00
  •  677.00
  •  601.00
  •  579.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4067699
  •  26592.90
  •  959.50
  •  313.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,151.27
  • 149.81
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,623.15
  • N/A
  • 3.93

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.33%
  • 12.01%
  • 23.94%
  • FII
  • DII
  • Others
  • 9.59%
  • 6.70%
  • 3.43%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.49
  • 4.87
  • 0.18

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.44
  • 1.93
  • 3.66

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.04
  • -27.26
  • -19.30

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.13
  • 29.95
  • 88.18

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.89
  • 2.27
  • 2.01

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.11
  • 21.87
  • 24.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
343.80
312.98
9.85%
292.51
260.18
12.43%
291.69
263.56
10.67%
286.48
262.50
9.14%
Expenses
257.79
252.68
2.02%
218.91
212.26
3.13%
221.63
225.34
-1.65%
220.54
231.21
-4.61%
EBITDA
86.01
60.30
42.64%
73.60
47.92
53.59%
70.06
38.23
83.26%
65.95
31.29
110.77%
EBIDTM
25.02%
19.27%
25.16%
18.42%
24.02%
14.50%
23.02%
11.92%
Other Income
4.99
1.81
175.69%
9.44
1.93
389.12%
2.49
2.17
14.75%
2.21
2.74
-19.34%
Interest
25.55
23.24
9.94%
23.74
18.15
30.80%
24.20
17.74
36.41%
26.22
17.86
46.81%
Depreciation
28.28
27.79
1.76%
27.11
26.75
1.35%
26.63
25.69
3.66%
26.71
24.08
10.92%
PBT
37.16
11.08
235.38%
32.20
4.95
550.51%
27.85
-3.03
-
15.23
-7.91
-
Tax
18.83
7.60
147.76%
14.62
2.11
592.89%
3.21
3.82
-15.97%
9.46
-0.96
-
PAT
18.33
3.48
426.72%
17.58
2.84
519.01%
24.64
-6.85
-
5.77
-6.95
-
PATM
5.33%
1.11%
6.01%
1.09%
8.45%
-2.60%
2.01%
-2.65%
EPS
1.83
0.19
863.16%
1.44
0.14
928.57%
2.82
-0.93
-
0.53
-0.76
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
1,214.48
1,151.60
1,050.11
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
Net Sales Growth
10.49%
9.66%
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
 
Cost Of Goods Sold
408.38
407.24
416.04
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
Gross Profit
806.10
744.36
634.07
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
GP Margin
66.37%
64.64%
60.38%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
Total Expenditure
918.87
915.53
961.84
948.32
729.43
693.39
579.39
637.60
617.55
556.44
487.38
Power & Fuel Cost
-
52.41
56.79
52.43
40.25
38.76
33.57
28.86
26.30
21.90
19.29
% Of Sales
-
4.55%
5.41%
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
Employee Cost
-
281.49
286.39
264.49
235.31
196.59
176.40
149.35
127.87
90.09
82.30
% Of Sales
-
24.44%
27.27%
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
Manufacturing Exp.
-
82.69
110.32
124.11
91.29
79.19
61.23
59.96
52.55
45.35
36.55
% Of Sales
-
7.18%
10.51%
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
General & Admin Exp.
-
44.36
46.86
71.58
47.71
70.26
27.20
22.50
16.95
14.11
10.64
% Of Sales
-
3.85%
4.46%
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
Selling & Distn. Exp.
-
20.91
18.56
18.02
18.63
10.40
6.72
6.37
4.75
7.27
5.99
% Of Sales
-
1.82%
1.77%
1.57%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
Miscellaneous Exp.
-
26.42
26.89
34.49
25.51
20.47
17.23
14.68
17.32
11.54
5.99
% Of Sales
-
2.29%
2.56%
3.01%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
EBITDA
295.62
236.07
88.27
197.20
171.70
214.52
154.00
151.23
161.61
159.99
126.42
EBITDA Margin
24.34%
20.50%
8.41%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
Other Income
19.13
16.59
31.41
20.90
40.09
22.22
15.56
32.62
29.34
11.36
6.93
Interest
99.71
91.81
58.65
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
Depreciation
108.73
107.87
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
PBT
112.44
52.99
-34.47
97.13
135.95
188.40
123.82
143.96
157.17
144.28
107.89
Tax
46.12
22.39
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
35.22
Tax Rate
41.02%
37.87%
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
PAT
66.32
31.88
-32.48
60.66
147.78
156.50
120.28
112.43
113.71
109.84
73.69
PAT before Minority Interest
66.19
31.96
-30.92
60.58
146.20
154.91
117.52
110.05
110.59
106.24
72.62
Minority Interest
-0.13
-0.08
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
1.07
PAT Margin
5.46%
2.77%
-3.09%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
PAT Growth
986.63%
-
-
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
49.06%
 
EPS
6.78
3.26
-3.32
6.20
15.11
16.00
12.30
11.50
11.63
11.23
7.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
1,808.69
1,783.28
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
Share Capital
8.68
8.68
8.68
8.15
8.15
8.15
8.15
8.01
7.71
7.71
Total Reserves
1,800.01
1,774.60
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
Non-Current Liabilities
589.64
345.12
452.82
561.37
256.94
166.62
153.48
251.26
67.23
154.15
Secured Loans
560.16
242.92
353.49
473.87
164.48
80.39
67.09
141.20
0.03
71.03
Unsecured Loans
0.00
45.90
0.11
0.35
0.53
0.70
1.03
1.30
0.00
31.30
Long Term Provisions
22.43
17.65
19.08
15.48
26.17
21.77
20.32
16.89
13.96
11.75
Current Liabilities
693.35
784.45
611.54
543.29
410.82
253.44
265.84
236.90
222.07
189.06
Trade Payables
174.82
142.80
146.04
67.25
92.55
80.72
103.74
111.86
106.48
75.50
Other Current Liabilities
137.21
276.56
240.13
219.33
142.10
81.62
59.59
28.03
36.49
49.32
Short Term Borrowings
360.73
344.17
202.90
243.40
165.27
86.58
98.12
92.41
74.10
58.47
Short Term Provisions
20.58
20.92
22.46
13.31
10.89
4.52
4.39
4.60
5.00
5.77
Total Liabilities
3,082.94
2,903.93
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
Net Block
1,384.86
1,368.33
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
Gross Block
1,946.75
1,846.68
1,727.09
1,421.10
986.42
853.16
793.24
704.89
582.20
476.34
Accumulated Depreciation
561.89
478.35
385.25
310.57
335.98
295.15
259.04
212.96
188.79
160.28
Non Current Assets
2,206.12
2,134.37
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
576.77
Capital Work in Progress
718.78
655.33
506.18
541.29
666.25
429.12
209.85
140.51
91.90
221.62
Non Current Investment
39.91
42.66
34.23
21.22
10.45
2.25
20.79
27.99
34.15
0.19
Long Term Loans & Adv.
53.32
56.53
93.90
43.10
32.42
48.75
37.47
77.09
51.86
38.74
Other Non Current Assets
9.25
11.52
12.15
13.46
5.78
26.84
24.86
4.80
5.36
0.16
Current Assets
876.83
769.55
887.19
818.99
623.85
545.06
671.97
729.88
354.21
327.61
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
119.54
224.62
59.63
65.35
Inventories
344.93
319.82
355.24
316.84
226.43
187.67
188.71
190.00
134.23
130.78
Sundry Debtors
392.05
324.35
386.33
217.50
246.79
203.73
220.27
170.93
125.43
81.37
Cash & Bank
30.44
21.56
34.11
123.11
44.56
94.54
73.83
100.39
11.03
18.42
Other Current Assets
109.42
15.53
9.36
98.73
106.06
59.12
69.62
43.95
23.90
31.69
Short Term Loans & Adv.
90.60
88.29
102.16
62.81
29.25
14.08
43.54
21.95
8.90
4.91
Net Current Assets
183.48
-14.89
275.66
275.69
213.04
291.62
406.13
492.98
132.14
138.55
Total Assets
3,082.95
2,903.92
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
135.34
179.92
105.13
46.93
124.38
146.78
44.92
37.48
128.70
68.81
PBT
54.34
-38.28
102.26
196.79
188.40
143.70
136.77
146.49
140.36
107.84
Adjustment
205.77
147.81
109.34
4.03
41.32
20.44
18.83
17.19
20.61
26.46
Changes in Working Capital
-83.62
102.77
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
Cash after chg. in Working capital
176.49
212.30
139.62
94.53
166.57
182.85
85.94
71.08
158.27
94.19
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-41.15
-32.37
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-166.58
-232.61
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
Net Fixed Assets
-17.18
-22.18
384.16
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
Net Investments
-2.53
-6.42
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
Others
-146.87
-204.01
-651.48
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
Cash from Financing Activity
46.77
45.80
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
Net Cash Inflow / Outflow
15.53
-6.89
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
8.68
Opening Cash & Equivalents
19.07
25.62
122.85
44.31
34.13
73.83
99.97
7.05
3.61
9.19
Closing Cash & Equivalent
30.43
19.07
25.34
123.34
44.31
34.36
73.83
99.97
6.43
18.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
208.37
205.44
209.93
181.37
163.06
146.89
133.09
123.17
82.91
70.92
ROA
1.07%
-1.07%
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
ROE
1.78%
-1.71%
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
ROCE
5.49%
0.80%
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
Fixed Asset Turnover
0.61
0.59
0.73
0.75
0.99
0.89
1.06
1.22
1.36
1.34
Receivable days
113.53
123.51
98.75
94.03
90.56
105.51
90.20
69.00
52.26
43.99
Inventory Days
105.35
117.32
109.68
110.03
83.24
93.66
87.32
75.49
66.97
74.84
Payable days
142.34
126.70
106.00
107.72
47.69
58.00
61.51
60.89
60.10
62.86
Cash Conversion Cycle
76.54
114.12
102.43
96.33
126.11
141.17
116.00
83.61
59.13
55.97
Total Debt/Equity
0.52
0.45
0.37
0.57
0.29
0.16
0.18
0.24
0.14
0.34
Interest Cover
1.59
0.35
3.48
9.92
42.34
40.09
55.10
49.69
37.07
27.63

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Shilpa Medicare’s arm gets CEP from EDQM for API, Nifedipine
    19th Nov 2024, 12:42 PM

    Nifedipine is in a class of medications called calcium-channel blockers in the dihydropyridine subclass

    Read More
  • Shilpa Medicare’s arm gets CEP from EDQM for API Octreotide
    18th Nov 2024, 17:38 PM

    Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis

    Read More
  • USFDA concludes inspection at Shilpa Medicare’s Bengaluru unit
    31st Oct 2024, 12:30 PM

    The inspection concluded with the issuance of Form 483 with four observations

    Read More
  • Shilpa Medicare secures USFDA’s approval for Bortezomib Injection
    27th Aug 2024, 14:57 PM

    This is the first liquid injection for Bortezomib, approved for both subcutaneous and intravenous administration by the USFDA

    Read More
  • Shilpa Medicare completes phase-3 clinical studies of novel product SMLNUD07 - NorUDCA
    26th Aug 2024, 10:41 AM

    NorUDCA is likely to be a first-in-class treatment option for NAFLD in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.